Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial 
Cancel anytime
- Chart
- Upturn Summary
- Highlights
- Valuation
- Analyst Ratings
Upturn AI SWOT - About
IO Biotech Inc (IOBT)
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- YEAR
- MONTH
- WEEK
Upturn Advisory Summary
06/27/2025: IOBT (1-star) is currently NOT-A-BUY. Pass it for now.
Upturn Star Rating
Not Recommended Performance
These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.
Number of Analysts
5 Analysts rated it
Moderately tracked stock, growing coverage, gaining market and investor attention.
1 Year Target Price $9.5
1 Year Target Price $9.5
| 2 | Strong Buy |
| 3 | Buy |
| 0 | Hold |
| 0 | Sell |
| 0 | Strong Sell |
Analysis of Past Performance
Type Stock | Historic Profit -63.16% | Avg. Invested days 16 | Today’s Advisory PASS |
Upturn Star Rating | Upturn Advisory Performance  2.0 | Stock Returns Performance  1.0 |
| Profits based on simulation | Last Close 06/27/2025 |
Key Highlights
Company Size Small-Cap Stock | Market Capitalization 94.87M USD | Price to earnings Ratio - | 1Y Target Price 9.5 |
Price to earnings Ratio - | 1Y Target Price 9.5 | ||
Volume (30-day avg) 5 | Beta 0.37 | 52 Weeks Range 0.66 - 1.73 | Updated Date 06/29/2025 |
52 Weeks Range 0.66 - 1.73 | Updated Date 06/29/2025 | ||
Dividends yield (FY) - | Basic EPS (TTM) -1.49 |
Earnings Date
Report Date - | When - | Estimate - | Actual - |
Profitability
Profit Margin - | Operating Margin (TTM) - |
Management Effectiveness
Return on Assets (TTM) -70.13% | Return on Equity (TTM) -138.78% |
Valuation
Trailing PE - | Forward PE - | Enterprise Value 57569088 | Price to Sales(TTM) - |
Enterprise Value 57569088 | Price to Sales(TTM) - | ||
Enterprise Value to Revenue - | Enterprise Value to EBITDA 1.36 | Shares Outstanding 65880900 | Shares Floating 31282893 |
Shares Outstanding 65880900 | Shares Floating 31282893 | ||
Percent Insiders 0.36 | Percent Institutions 66.46 |
Analyst Ratings
Rating 3 | Target Price 9.5 | Buy 3 | Strong Buy 2 |
Buy 3 | Strong Buy 2 | ||
Hold - | Sell - | Strong Sell - | |
Strong Sell - |
Upturn AI SWOT
IO Biotech Inc
Company Overview
History and Background
IO Biotech, Inc. is a clinical-stage biopharmaceutical company founded in 2013. They focus on developing immune-oncology therapies to treat cancer. The company leverages its T-winu00ae technology platform to design immunomodulatory therapies.
Core Business Areas
- Immuno-Oncology Therapeutics: Developing and commercializing immune-oncology therapies for the treatment of cancer.
Leadership and Structure
The leadership team includes Mai-Britt Zocca, PhD, CEO. The company has a Board of Directors and operates with functional departments overseeing R&D, clinical development, and operations.
Top Products and Market Share
Key Offerings
- IO102-IO103: IO102-IO103 is an immune-oncology therapy in clinical development. It's a combination therapy designed to target IDO and PD-L1. Market share data and revenue are not publicly available due to being in clinical development. Competitors include companies developing IDO and PD-L1 inhibitors such as Bristol Myers Squibb, Merck, and Roche.
Market Dynamics
Industry Overview
The immuno-oncology industry is rapidly growing, driven by the increasing prevalence of cancer and advancements in immunotherapy. There is high competition, and the area focuses on modulating the immune system to fight cancer.
Positioning
IO Biotech is positioned as an innovator in the immune-oncology space, focusing on novel combination therapies. Their competitive advantage lies in their T-winu00ae technology platform.
Total Addressable Market (TAM)
The global immuno-oncology market is estimated to be worth hundreds of billions USD. IO Biotech is positioned to capture a portion of this TAM with their innovative therapies.
Upturn SWOT Analysis
Strengths
- Proprietary T-winu00ae technology platform
- Focus on novel combination therapies
- Experienced management team
- Strong intellectual property portfolio
Weaknesses
- Limited financial resources compared to larger pharmaceutical companies
- Clinical trial risks and uncertainties
- Dependence on successful development and commercialization of lead product candidates
- No products currently approved for marketing
Opportunities
- Partnerships and collaborations with larger pharmaceutical companies
- Expansion into new cancer indications
- Potential for breakthrough therapies with improved efficacy and safety
- Positive clinical trial results driving stock value
Threats
- Competition from established pharmaceutical companies
- Regulatory hurdles and delays
- Failure to achieve clinical trial endpoints
- Patent challenges
Competitors and Market Share
Key Competitors
- BMY
- MRK
- RHHBY
Competitive Landscape
IO Biotech is a smaller player compared to its larger competitors. Its advantages include its novel technology platform and focus on combination therapies. Disadvantages include limited financial resources and lack of approved products.
Growth Trajectory and Initiatives
Historical Growth: Historical growth analysis is not provided, as this analysis does not have access to real-time financial data.
Future Projections: Future growth projections depend on clinical trial outcomes and regulatory approvals.
Recent Initiatives: Recent initiatives include advancing IO102-IO103 through clinical trials.
Summary
IO Biotech is a clinical-stage company focusing on innovative immunotherapies. Its T-win platform is a key strength, but it faces challenges due to being smaller than its competitors. Positive clinical trial results are crucial for future growth, with regulatory hurdles and the need to secure partnerships representing potential obstacles.
Peer Comparison
Sources and Disclaimers
Data Sources:
- Company Website
- SEC Filings
- Industry Reports
- Market Research Reports
Disclaimers:
This analysis is for informational purposes only and does not constitute financial advice. The data and analysis are based on available information and subject to change. Market share data are estimates and may not be precise.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About IO Biotech Inc
Exchange NASDAQ | Headquaters - | ||
IPO Launch date 2021-11-05 | Founder, President, CEO, Principal Financial Officer & Director Dr. Mai-Britt Zocca Ph.D. | ||
Sector Healthcare | Industry Biotechnology | Full time employees 79 | Website https://www.iobiotech.com |
Full time employees 79 | Website https://www.iobiotech.com | ||
IO Biotech, Inc., a clinical-stage biopharmaceutical company, develops immune-modulating therapeutic cancer vaccines based on the T-win technology platform. The company's lead therapeutic cancer vaccine candidate includes IO102-IO103, which targets cancer cells and immune-suppressive cells in the tumor microenvironment that express indoleamine 2,3-dehydrogenase (IDO), and programmed death-ligand (PD-L1) that is in phase 3 clinical trial to treat melanoma, as well as in phase 2 clinical trial to treat lung, head and neck, and melanoma cancer. It also develops IO112, a product candidate that contains a single Arginase 1-derived peptide to target T cells that recognize epitopes derived from Arginase 1, which is an immunoregulatory enzyme highly expressed in difficult-to-treat tumors associated with high levels of myeloid-derived suppressor cells, including renal cell carcinoma, head and neck, breast, pancreatic, ovarian, colorectal, and prostate cancers. In addition, the company develops IO170, a TGFß1 vaccine for the treatment of solid tumors. IO Biotech, Inc. was incorporated in 2014 and is based in Copenhagen, Denmark.
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.